Hikma Pharmaceuticals

UK-headquartered pharmaceutical company

HIK London SE ISIN GB00B0LCW083 LEI 549300BNS685UXH4JI75
Follow Hikma Pharmaceuticals Weekly email: filings, results

Financials

Reported figures only · latest: fiscal 2025 USD · IFRS
Revenue, last year $3.3B +7.1% vs prior year
Net income $402M +12% vs prior year
EPS, diluted $1.81 +12.4% vs prior year
Operating cash flow $436M −22.7% vs prior year
Revenue by fiscal year
$2.3B
$2.6B
$2.5B
$2.9B
$3.1B
$3.3B
FY20 FY21 FY22 FY23 FY24 FY25

Source: ESEF annual reports · latest filing

The long view

Fiscal years as reported · ESEF annual reports, IFRS
Revenue and net income6 fiscal years
  • Revenue
  • Net income
$0$1B$2B$3B$4BFY20FY21FY22FY23FY24FY25
Show the numbers
YearRevenueNet income
FY25$3.3B$402M
FY24$3.1B$359M
FY23$2.9B$190M
FY22$2.5B$188M
FY21$2.6B$421M
FY20$2.3B$431M
MarginsShare of revenue
  • Gross margin
  • Operating margin
  • Net margin
0%20%40%60%FY20FY21FY22FY23FY24FY25
Show the numbers
YearGross marginOperating marginNet margin
FY2543%16.2%12%
FY2445.3%19.6%11.5%
FY2348.3%12.8%6.6%
FY2249.2%11.2%7.5%
FY2151%22.8%16.5%
FY2051.3%24.7%18.4%
Free cash flowOperating cash flow minus capital expenditure
$0$200M$400M$600MFY20FY21FY22FY23FY24FY25
Show the numbers
YearFree cash flow
FY25$239M
FY24$399M
FY23$439M
FY22$392M
FY21$493M
FY20$292M
Returned to shareholdersDividends paid and shares bought back
  • Dividends
  • Buybacks
$0$200M$400M$600MFY20FY21FY22FY23FY24FY25
Show the numbers
YearDividendsBuybacks
FY25$185M$36M
FY24$175M$38M
FY23$137M$0
FY22$125M$300M
FY21$120M$0
FY20$109M$375M
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • Hikma Pharmaceuticals
  • Healthcare median
−100%−75%−50%−25%0%25%FY20FY21FY22FY23FY24FY25
Show the numbers
YearHikma PharmaceuticalsHealthcare median
FY2512%−30.6%
FY2411.5%−47%
FY236.6%−58%
FY227.5%−80.4%
FY2116.5%−71.9%
FY2018.4%−62.2%